TY - JOUR
T1 - Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma
AU - Torres-Cabala, Carlos
AU - Li-Ning-Tapia, Elsa
AU - Hwu, Wen Jen
N1 - Publisher Copyright:
© 2020 IMSS
PY - 2020/11
Y1 - 2020/11
N2 - The dramatic recent advances in therapy of melanoma require a more personalized and precise diagnostic approach to aid in clinical decisions. Tissue-based biomarkers in pathology have diagnostic, prognostic and predictive relevance. Herein we review the most commonly used pathology-based biomarkers in melanoma. Most of these biomarkers are evaluated through immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) performed on formalin fixed paraffin embedded tissue (FFPE), and are widely available in clinical pathology laboratories. We describe the utility of MART1/Ki67, p16, PRAME, markers of lymphovascular invasion (D2-40, CD31, D2-40/MITF, CD31/SOX-10), BRAF V600E, NRAS, KIT, BAP1, ALK, NTRK, PD-L1, TERT, PTEN, iNOS, and MMR proteins (MLH1, MSH2, MSH6, PMS2) in the evaluation of melanoma specimens. Correct interpretation and awareness of the significance of these biomarkers is crucial for pathologists, dermatologists, and oncologists who take care of melanoma patients.
AB - The dramatic recent advances in therapy of melanoma require a more personalized and precise diagnostic approach to aid in clinical decisions. Tissue-based biomarkers in pathology have diagnostic, prognostic and predictive relevance. Herein we review the most commonly used pathology-based biomarkers in melanoma. Most of these biomarkers are evaluated through immunohistochemistry (IHC) or fluorescent in situ hybridization (FISH) performed on formalin fixed paraffin embedded tissue (FFPE), and are widely available in clinical pathology laboratories. We describe the utility of MART1/Ki67, p16, PRAME, markers of lymphovascular invasion (D2-40, CD31, D2-40/MITF, CD31/SOX-10), BRAF V600E, NRAS, KIT, BAP1, ALK, NTRK, PD-L1, TERT, PTEN, iNOS, and MMR proteins (MLH1, MSH2, MSH6, PMS2) in the evaluation of melanoma specimens. Correct interpretation and awareness of the significance of these biomarkers is crucial for pathologists, dermatologists, and oncologists who take care of melanoma patients.
KW - Biomarkers
KW - Fluorescent in situ hybridization
KW - Immunohistochemistry
KW - Melanoma
KW - Oncology
KW - Pathology
UR - http://www.scopus.com/inward/record.url?scp=85090997094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090997094&partnerID=8YFLogxK
U2 - 10.1016/j.arcmed.2020.09.008
DO - 10.1016/j.arcmed.2020.09.008
M3 - Review article
C2 - 32950263
AN - SCOPUS:85090997094
SN - 0188-4409
VL - 51
SP - 827
EP - 838
JO - Archives of Medical Research
JF - Archives of Medical Research
IS - 8
ER -